Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

SUPN

+ Watchlist+ Portfolio

Supernus Pharmaceuticals, Inc.

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$29.04
52-Week Range
$25.92 – $42.81
Market Cap
$6.02B
P/E (TTM)
—
EPS (TTM)
-0.76
Dividend Yield
0.00%
Advanced Metrics
Price/Book
—
PEG Ratio
—
Return on Equity
—
Return on Assets
29.34%
Gross Margin
85.73%
Operating Margin
46.94%
Profit Margin
32.75%
Current Ratio
0.61
Debt/Equity
—
Total Debt
$501.00M
Free Cash Flow
$227.12M
Revenue Growth
13.40%
Earnings Growth
239.40%
Enterprise Value
$3.61B

Market Snapshot

About

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company markets FDA-approved medications for epilepsy, ADHD, and other neurological conditions. Supernus has a pipeline of additional product candidates in various stages of clinical development.